In addition, RALA gene has almost no mutation in Follicular Thyroid Cancer, Desmoplastic/Nodular Medulloblastoma, Cervical squamous cell cancer and endocervical adenocarcinoma (CESC), LAML, Chronic Lymphocytic Leukemia/Small Lymphocytic, Essential Thrombocythemia, Follicular lymphoma, Polycythemia vera, Invasive Breast Cancer and Liposarcoma (Figure 5A). This evidence concerns the gene RALA and essential thrombocythemia.